Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Dime La VerDAD: Verify, Debunk, and Disseminate

NCT06417762 · View on ClinicalTrials.gov ↗

Study Summary

Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity and mortality due to respiratory virus infections. Dime La Verdad is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers community health workers to disseminate reliable information about respiratory virus protection strategies through the use of personal narratives on social media. The proposed work will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in principles of health communication, 2) evaluate how diffusion of health messaging is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can encourage informed decision-making to promote evidence-based immunization practices and improve health outcomes.

Interventions

  • BEHAVIORAL Science Communication Curriculum Cohort 1
  • BEHAVIORAL Science communication curriculum Cohort 2
  • BEHAVIORAL Science communication curriculum Cohort 3
  • BEHAVIORAL Science communication curriculum Cohort 4

Study Locations (4)

Illinois

  • Rush University — Chicago
  • University of Chicago — Chicago

Iowa

  • University of Iowa — Iowa City

Michigan

  • University of Michigan — Ann Arbor

Trial Details

FieldValue
Enrollment Target 1,400 participants
Start Date 2024-07-02
Est. Completion 2029-04-01
Phase NA

Sponsor

University of Chicago

846 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06417762

The ClinicalTrials.gov registry entry for NCT06417762 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 846 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions — of which Science Communication Curriculum Cohort 1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06417762 reports 4 study locations spanning 3 distinct geographic areas — top geographies include Illinois, Iowa, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06417762 about?

NCT06417762 is a clinical study titled "Dime La VerDAD: Verify, Debunk, and Disseminate". Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity ...

What is the current status of trial NCT06417762?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2024-07-02. Estimated completion is 2029-04-01.

What conditions does trial NCT06417762 study?

This clinical trial studies the following conditions: COVID-19, Influenza, Health Behavior, Communication Research, Respiratory Viral Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06417762?

The interventions under investigation include: Science Communication Curriculum Cohort 1 (BEHAVIORAL), Science communication curriculum Cohort 2 (BEHAVIORAL), Science communication curriculum Cohort 3 (BEHAVIORAL), Science communication curriculum Cohort 4 (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06417762?

This trial is sponsored by University of Chicago, which has 846 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06417762 being conducted?

This trial has 4 study locations across Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial